Novartis | NVS - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
AbbVie USD 12.48B 110M 2026-03
Amgen USD 10.23B 1.09B 2026-06
AstraZeneca USD 18.86B 972M 2026-06
Bausch Health Companies USD 2.26B 72M 2026-06
Biogen USD 2.38B 15.8M 2026-09
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Canopy Growth CAD 36.29M 104.13M 2026-03
Corcept Therapeutics USD 76.92M 37.85M 2026-06
Drreddys Laboratories INR 123.17B 121.76B 2026-03
Eli Lilly USD 23.48B 2.3B 2026-06
Gilead Sciences USD 5.06B 314M 2026-06
GlaxoSmithKline GBP 8.52B 451M 2026-09
Glaxosmithkline GBP 10.49B 40.6M 2026-03
J&J USD 19.05B 3.49B 2026-06
Merck USD 12.21B 435M 2026-03
Novartis USD 9.85B 252M 2026-06
Novartis USD 9.6B 2.69B 2026-03
Pacira USD 132.42M 6.78M 2026-06
Perrigo USD 697.1M 84.3M 2026-03
Pfizer USD 16.19B 19M 2026-06
Phibro Animal Health USD 215.87M 2.02M 2025-12
Prestige Brands USD 187.36M 4.56M 2026-06
Roche Holding CHF 13.34B 1.44B 2026-06
Sanofi EUR 492M 10M 2026-06
Sanofi EUR 482M 85M 2026-03
Supernus Pharmaceuticals USD 211.66M 29.47M 2026-06
Zoetis USD 1.57B 65M 2026-06